GlassScriptPhysician profile
George Paul Fahed
NPI 1003850397
$16,239.28
in general payments reported to CMS, 2019-2025
25 companies · $2,454 in 2025
The $2,454 reported for 2025 was more than what 79% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,456 · 2020: $584 · 2021: $1,026 · 2022: $690 · 2023: $1,222 · 2024: $1,807 · 2025: $2,454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,076 · Education: $407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,075.60 |
| Education | $407.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $7,126.15 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $2,486.03 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $1,714.73 | 2019-2025 | Nucala, Arexvy |
| Jazz Pharmaceuticals INC. | $1,002.99 | 2019-2025 | |
| United Therapeutics Corporation | $770.99 | 2019-2025 | Tyvaso, Tyvaso |
| Merck Sharp & Dohme LLC | $593.70 | 2023-2025 | Winrevair, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $592.20 | 2019-2022 | |
| Harmony Biosciences LLC | $440.69 | 2023-2025 | Wakix |
| Genzyme Corporation | $327.14 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $236.89 | 2021-2025 | Glassia, Hyqvia |
| Actelion Pharmaceuticals US, INC. | $163.61 | 2019-2025 | Uptravi, Opsumit |
| E.R. Squibb & Sons, L.L.C. | $124.46 | 2019 | |
| Janssen Pharmaceuticals, INC | $104.66 | 2020-2023 | Xarelto |
| Mallinckrodt Hospital Products INC. | $99.43 | 2023 | Acthar |
| Mallinckrodt Enterprises LLC | $94.63 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $71.40 | 2020-2021 | |
| Genentech USA, INC. | $62.93 | 2019-2023 | Xolair |
| Viatris Specialty LLC | $55.40 | 2025 | Yupelri |
| Mylan Specialty L.P. | $49.89 | 2023-2024 | Yupelri |
| Medtronic, INC. | $33.34 | 2025 | Endurant Iis |
| Shire North American Group INC | $27.67 | 2019 | |
| Amgen INC. | $24.41 | 2023 | Tezspire |
| Mylan LLC | $15.95 | 2019 | |
| Pbg Puerto Rico LLC | $15.05 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $4.94 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Fahed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.